Press Release – For immediate release – 5:45 PM CET
Yearly Median Technologies liquidity contract statement contracted with AUREL BGC Company
Under the liquidity contract entrusted by Median Technologies to AUREL BGC, the following resources were listed in the liquidity account as of December 31, 2019:
- €141,002.52
- 22,458 shares
- Transactions:
| BUY | 129,054 shares | €217,013.37 | 256 transactions |
| SELL | 156,230 shares | €264,113.08 | 256 transactions |
For information, as of June 30, 2019, the following resources were listed in the liquidity account:
- €104,740.61
- 43,401 shares
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.